Serious Skincare Serious C3 Plasma Bio Technology C Vitamin C Ester Protective Daytime Broad Spectrum Moisturizer Spf 30 Cream
NDC Package 53755-101-04
Package Information
Serious Skincare Serious C3 Plasma Bio Technology C Vitamin C Ester Protective Daytime Broad Spectrum Moisturizer Spf 30 (avobenzone, octocrylene, octinoxate, octisalate, oxybenzone) cream is apply liberally and evenly 15 minutes before sun exposureReapply at least every 2 hoursUse a water resistant sunscreen if swimming or sweatingSun Protection Measures: Spending time in the sun increases your risk of skin cancer and early skin aging. This formulation utilizes a cream delivery system. Marketed by Flageoli Limited, this product is identified by NDC 53755-101 and is authorized under FDA application M020.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 53755 - Flageoli Limited
- 53755-101 - Serious Skincare Serious C3 Plasma Bio Technology C Vitamin C Ester Protective Daytime Broad Spectrum Moisturizer Spf 30
- 53755-101-04 - 1 TUBE in 1 BOX / 120 mL in 1 TUBE
- 53755-101 - Serious Skincare Serious C3 Plasma Bio Technology C Vitamin C Ester Protective Daytime Broad Spectrum Moisturizer Spf 30
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 53755-101-04 identifies a specific commercial package of 1 tube in 1 box / 120 ml in 1 tube of Serious Skincare Serious C3 Plasma Bio Technology C Vitamin C Ester Protective Daytime Broad Spectrum Moisturizer Spf 30, a human over the counter drug labeled by Flageoli Limited. This cream is formulated for topical use and contains avobenzone; octinoxate; octisalate; octocrylene; oxybenzone as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Flageoli Limited on July 01, 2021. The current certification is valid through December 31, 2026.
How is this Flageoli Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 53755010104. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.